Analyses revealed no significant differences in readmission rates (2.3% in colchicine group and 2.3% in placebo group, p-value = 0.513), functional capacity (p-value = 0.857), left ventricular end-diastolic size (LVEDD) (p-value = 0.194), LVEF (p-value = 0.354), C-reactive protein (CRP) levels (p-value = 0.444), incidence of atrial fibrillation (AF) (p-value = 0.312), and left ventricular thrombosis after the 40-day follow-up period (p-value = 0.650). Here, CRP is linked to atrial fibrillation.